Asthma – severe eosinophilic asthma

The PBS subsidises mepolizumab for patients with uncontrolled severe eosinophilic asthma.

Patient eligibility

Treatment with mepolizumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 100 – Highly Specialised Drugs (HSD) Program, for patients with uncontrolled severe eosinophilic asthma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing mepolizumab.

Section 100 arrangements

This item is available to a patient who is attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

and is either a

  • day admitted patient
  • non-admitted patient, or
  • patient on discharge

This item is not available as a PBS benefit for hospital in-patients. You need to include the hospital name and provider number on the authority application form.

Toxicity and severity descriptors

Use the severe asthma toxicity criteria and severity descriptors with the authority application when demonstrating patients' intolerance to prior therapies.  

Applications

All applications must be completed by the treating respiratory physician, clinical immunologist, allergist or general physician with expertise in the management of uncontrolled severe eosinophilic asthma.

Initial treatment

Make all initial applications for authority approval to prescribe mepolizumab for the treatment of uncontrolled severe eosinophilic asthma in writing and:

All applications must include the completed:

You must submit a completed Asthma Control Questionnaire 5-item (ACQ-5) calculation sheet with the application. You can contact GlaxoSmithKline Medical Information to obtain this sheet.

Grandfather treatment

For patients who received non-PBS subsidised mepolizumab before 1 January 2017 for the treatment of uncontrolled severe eosinophilic asthma, make all initial grandfather applications in writing and:

Applications must include the completed:

Continuing treatment

Make all applications for continuing authority approval to prescribe mepolizumab for the treatment of uncontrolled severe eosinophilic asthma in writing and:

Applications must include the completed:

You must submit a completed ACQ-5 calculation sheet with the application. Contact GlaxoSmithKline Medical Information to obtain this sheet.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 March 2018